EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the balance.
The European Medicines Agency has proposed revoking the marketing authorization for Amgen’s controversial rare disease drug Tavneos citing “incorrect and misleading” clinical data.
The future …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
European Regulators Move to Revoke Avacopan Authorization
On second try, Acadia drug gets nod from European regulators
Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Omeros (NASDAQ:OMER)
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
FDA reverses course on Regenxbio’s childhood gene therapy after rejection
FDA Reverses Course on Neuro Drugs; Omega-3s and Dementia; Brain Death Test Lawsuit
